Log in

NASDAQ:EVFMEvofem Biosciences Stock Price, Forecast & News

-0.07 (-1.27 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $5.46
50-Day Range
MA: $5.19
52-Week Range
Now: $5.46
Volume1.78 million shs
Average Volume1.94 million shs
Market Capitalization$271.47 million
P/E RatioN/A
Dividend YieldN/A
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Read More
Evofem Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EVFM



Sales & Book Value

Annual SalesN/A
Book Value$0.02 per share


Net Income$-80,030,000.00


Market Cap$271.47 million
Next Earnings Date8/3/2020 (Estimated)
OptionableNot Optionable

Receive EVFM News and Ratings via Email

Sign-up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions

How has Evofem Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EVFM shares have increased by 5.8% and is now trading at $5.46. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Evofem Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evofem Biosciences.

When is Evofem Biosciences' next earnings date?

Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Evofem Biosciences.

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences Inc (NASDAQ:EVFM) released its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.40) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.32) by $0.08. View Evofem Biosciences' earnings history.

What price target have analysts set for EVFM?

4 Wall Street analysts have issued 12-month target prices for Evofem Biosciences' stock. Their forecasts range from $6.00 to $25.00. On average, they expect Evofem Biosciences' share price to reach $12.75 in the next twelve months. This suggests a possible upside of 133.5% from the stock's current price. View analysts' price targets for Evofem Biosciences.

Has Evofem Biosciences been receiving favorable news coverage?

Media stories about EVFM stock have trended neutral this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evofem Biosciences earned a daily sentiment score of 0.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days. View the latest news aboutEvofem Biosciences.

Are investors shorting Evofem Biosciences?

Evofem Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,140,000 shares, an increase of 41.7% from the April 30th total of 1,510,000 shares. Based on an average trading volume of 173,900 shares, the short-interest ratio is presently 12.3 days. Approximately 6.3% of the shares of the company are short sold. View Evofem Biosciences' Current Options Chain.

Who are some of Evofem Biosciences' key competitors?

What other stocks do shareholders of Evofem Biosciences own?

Who are Evofem Biosciences' key executives?

Evofem Biosciences' management team includes the following people:
  • Ms. Saundra Pelletier, CEO & Director
  • Mr. Justin J. File, Chief Financial Officer (Age 49)
  • Dr. Kelly Culwell, Chief Medical Officer
  • Mr. Jason Abrams, Accounting Mang.
  • Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

Who are Evofem Biosciences' major shareholders?

Evofem Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.01%), Schroder Investment Management Group (6.42%), State Street Corp (0.55%), Geode Capital Management LLC (0.53%), Squarepoint Ops LLC (0.07%) and Oppenheimer & Co. Inc. (0.06%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Justin J File, Kelly Culwell, Kim P Kamdar, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View institutional ownership trends for Evofem Biosciences.

Which institutional investors are selling Evofem Biosciences stock?

EVFM stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, UBS Group AG, State Street Corp, and Deutsche Bank AG. Company insiders that have sold Evofem Biosciences company stock in the last year include Justin J File, Kelly Culwell, Russell Barrans, and Saundra L Pelletier. View insider buying and selling activity for Evofem Biosciences.

Which institutional investors are buying Evofem Biosciences stock?

EVFM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Squarepoint Ops LLC, Oppenheimer & Co. Inc., and Geode Capital Management LLC. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier, and Thomas G Lynch. View insider buying and selling activity for Evofem Biosciences.

How do I buy shares of Evofem Biosciences?

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $5.46.

How big of a company is Evofem Biosciences?

Evofem Biosciences has a market capitalization of $271.47 million. The biotechnology company earns $-80,030,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe.

What is Evofem Biosciences' official website?

The official website for Evofem Biosciences is www.evofem.com.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.